Tarsus Pharmaceuticals (TARS) EBT Margin (2021 - 2026)
Tarsus Pharmaceuticals' (TARS) quarterly EBT Margin came in at 2.79% in Q1 2026, up 2917.0% year-on-year from 0.09% in Q1 2025, and up 32.09% quarter-over-quarter from 4.11% in Q4 2025.
Tarsus Pharmaceuticals (TARS) EBT Margin (2021 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' EBT Margin history runs 6 years deep, the most recent figure standing at 2.79% for Q1 2026.
- On a quarterly basis, EBT Margin rose 2917.0% year-over-year to 2.79% in Q1 2026; TTM through Mar 2026 was 27.5%, a 1655.0% increase from a year earlier, with the FY2025 full-year figure at 14.26%, up 4890.0% from the prior year.
- EBT Margin rose to 2.79% in Q1 2026 per TARS's latest filing, from 4.11% in the prior quarter.
- Across five years, EBT Margin topped out at 2.79% in Q1 2026 and bottomed at 3680.33% in Q1 2022.
- The 5-year median for EBT Margin is 76.64% (2024), against an average of 509.77%.
- Biggest YoY gain for EBT Margin was 414354 bps in 2022; the steepest drop was 371208 bps in 2022.
- Year by year, EBT Margin stood at 131.02% in 2022, then plunged by 148 bps to 324.72% in 2023, then soared by 89 bps to 34.84% in 2024, then surged by 88 bps to 4.11% in 2025, then surged by 32 bps to 2.79% in 2026.
- Per Business Quant, the three latest TARS EBT Margin figures stand at 2.79% (Q1 2026), 4.11% (Q4 2025), and 10.69% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Tarsus Pharmaceuticals | 2.52 Bn | 2.41 Bn | 152.66 Mn | -2.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.79% |
| Dec 31, 2025 | -4.11% |
| Sep 30, 2025 | -10.69% |
| Jun 30, 2025 | -120.49% |
| Mar 31, 2025 | -31.96% |
| Dec 31, 2024 | -34.84% |
| Sep 30, 2024 | -48.81% |
| Jun 30, 2024 | -76.64% |
| Mar 31, 2024 | -128.74% |
| Dec 31, 2023 | -324.72% |
| Sep 30, 2023 | -2,081.93% |
| Mar 31, 2023 | -933.72% |
| Dec 31, 2022 | -131.02% |
| Jun 30, 2022 | -35.81% |
| Mar 31, 2022 | -3,680.33% |
| Dec 31, 2021 | -4,274.56% |
| Sep 30, 2021 | -1,265.89% |
| Jun 30, 2021 | 32.70% |
| Mar 31, 2021 | 31.75% |